GRANTS / FUNDING
Funding for Phase 1 & 2
In July 2018, a scientific development program began and a grant proposal is expected for submission in 2019/2020.
WPD103 has not been submitted for FDA or EMA approval so far.
PARTNERS, AFFILIATIONS & LICENSE
Wake Forest Baptist Medical Center
Recognized, fully integrated academic medical center and health system located in Winston-Salem, North Carolina, USA.
North Carolina Baptist Hospital
Operates inpatient hospitals, community health centers, health maintenance organization, primary care centers and teaching hospital as a subsidiary of Wake Forest Baptist Medical Center.
Lower Silesian Center of Oncology
In Wroclaw, Poland, drug development
WPD103 is currently in preclinical development and based on the data obtained from in vitro studies using cancer cell lines and WPD101 in spontaneous GBM dog model studies, we see significant potential for WPD103 in diagnostics and therapy in humans. Phase I clinical trial is expected to begin in 2022-23.
Primary focus on cancers with high overexpression of IL-13RA2 (for example melanoma lesion in liver).
In addition to GBM and melanoma, pancreatic, breast and colon cancer cells also express a high level of IL-13RA2 receptors. WPD Pharmaceuticals is going to develop WPD103 as a diagnostic tool first and targeted therapy in progressed melanoma later.